Transcraniële magnetische stimulatie, of TMS, behandelt depressie die niet heeft gereageerd op medicatie. Een clinician houdt een elektromagnetische spoel tegen de hoofdhuid en stuurt korte magnetische pulsen naar de onderliggende cortex die de stemming reguleert. De behandeling wordt in een kliniek gegeven terwijl de persoon wakker zit, in dagelijkse sessies gedurende vier tot zes weken. Het is een van de beter onderbouwde opties voor therapieresistente depressie. In gerandomiseerde proeven reageert ongeveer drie op de tien personen en bereikt ongeveer één op de vijf remissie, enkele malen hoger dan het percentage dat wordt gezien met een uitgeschakelde schijnspoel.
Een nieuwere vorm, intermittente theta-burst stimulatie, bereikt hetzelfde resultaat in een sessie van drie minuten in plaats van dertigzeven. Een intensief protocol van vijf dagen bracht de meeste deelnemers van een kleine proef in remissie. Het effect is echt en reproduceerbaar. Het is geen genezing: de meeste personen bereiken geen remissie, de reactie op schijnbehandeling is aanzienlijk, en het voordeel kan over het volgende jaar verdwijnen zonder onderhoudssessies. TMS is ook goedgekeurd voor obsessief-compulsieve stoornis en als hulpmiddel bij het stoppen met roken.
Findings & Outcomes
What It Is
Transcranial magnetic stimulation is a clinic treatment that uses a magnetic field to influence a targeted patch of the brain from outside the skull. An electromagnetic coil is held against the scalp, usually over the left front of the head, and the machine sends rapid magnetic pulses through it. Each pulse passes painlessly through the skull. In the cortex just beneath the coil it induces a small electrical current that makes nearby neurons fire. A standard session runs 20 to 40 minutes. TMS is delivered in a clinic, never at home.
How It Works
A single pulse produces only a momentary effect. The treatment works by repetition: pulses delivered in a rhythm, session after session, change how excitable that patch of cortex remains for a while after each session ends. The direction depends on speed. Delivered at a fast rhythm, around 10 pulses a second, the pulses tend to raise excitability in the target; delivered near 1 a second they tend to lower it.
What Happens Across a Course of Treatment
1The first session, and finding the dose
The clinician first measures the motor threshold: pulses over the area that controls the hand, turned up until the thumb twitches, which sets the strength for that person. The treatment coil then moves to the left dorsolateral prefrontal cortex, a region on the mood-regulating network. Pulses feel like a firm tapping on the scalp.
2The daily course
Sessions run once a day, five days a week, for four to six weeks in the standard protocol. The antidepressant effect builds over these weeks, not in one session, the excitability shift accumulates. Faster variants exist: intermittent theta-burst stimulation shortens each session, and an accelerated protocol packs many short sessions into each day to finish in under a week.
3After the course, and repeating it
A course treats the current depressive episode, then ends. If depression returns later, another course can follow.
The specific rhythm behind most of the newer research is theta-burst stimulation. It packs the pulses into short high-frequency bursts repeated about five times a second, matching the brain's theta rhythm. In healthy volunteers, this pattern applied over the motor cortex changed cortical excitability for up to an hour, after stimulation lasting only one to two minutes. The direction again split by pattern. Intermittent bursts raised excitability, resembling long-term potentiation, the strengthening of connections that underlies learning. Continuous bursts lowered it, resembling long-term depression. The motor-cortex effect is directly measured and well established. Applying it to how repeated prefrontal sessions lift mood is inference, and individual response varies.
The Forms And Their Evidence
TMS is not one procedure. Different coils, rhythms, and targets hold separate FDA clearances, each with its own trial base.
Standard rTMS For Depression
Repetitive TMS over the left prefrontal cortex is the oldest and best-evidenced use. The FDA cleared it in 2008 for major depression that had not responded to medication. In the NIMH-sponsored OPT-TMS trial, 190 adults received daily left prefrontal rTMS or a sham procedure as their only antidepressant. Remission reached about 14% with active treatment versus 5% with sham over three weeks. A larger meta-analysis pooled 29 randomized, sham-controlled trials in 1,371 people. High-frequency rTMS produced response in 29.3% and remission in 18.6%, against 10.4% and 5% with sham. That works out to about one extra person responding for every 6 treated. Most people still do not reach remission. The sham response, near one in ten, means part of what any individual feels comes from expectation and the attention of daily visits.
Theta-Burst And Accelerated Protocols
A standard session's length limits how many people a clinic can treat. Intermittent theta-burst stimulation delivers the same course in about three minutes. The THREE-D trial put that to the test in 414 adults with treatment-resistant depression. The shorter session matched standard 10 Hz rTMS: response of 49% versus 47%, remission of 32% versus 27%, with similar side effects. That equivalence is why theta-burst is now widely used. A more intensive approach compresses the whole course. Stanford Neuromodulation Therapy delivers 10 short sessions a day for five days, each target guided by the person's brain scan. In a double-blind trial of 29 people, 79% of the active group reached remission at some point in the following month, against 13% with sham. That trial was small and single-site. It sits at an earlier stage of evidence, and awaits confirmation before the number is taken at face value.
Deep TMS For OCD
A deeper-reaching coil, worn like a helmet, targets circuits set further in than the standard figure-eight coil can reach. On that basis the FDA cleared deep TMS for obsessive-compulsive disorder in 2018. The pivotal trial was multicenter and double-blind, in 99 adults. Deep TMS over the medial prefrontal and anterior cingulate cortex was delivered right after a brief symptom-provocation. It produced response in 38.1% versus 11.1% with sham, and the gain held a month later. Response meant at least a 30% drop in symptoms: many people were improved but still far from symptom-free.
Deep TMS As An Aid To Quitting Smoking
In 2020 deep TMS became the first brain-stimulation treatment the FDA cleared to help adults stop smoking. The pivotal trial enrolled 262 chronic smokers. Deep TMS to the prefrontal and insular cortices, given right after a craving cue, produced a four-week continuous quit rate of 19.4% through week 18, versus 8.7% with sham. Most people still smoked, so it supports the effort of quitting rather than replacing it.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
Theta-burst TMS shifted human cortex excitability for up to an hour, up or down by pattern
Brief patterned magnetic pulses can nudge the brain's activity up or down, and the change outlasts the pulses, which is how repeated sessions are thought to shift the mood-regulating cortex over a course of treatment.
Huang and colleagues adapted the theta-burst protocol used to induce synaptic long-term potentiation and depression in brain slices into a TMS protocol over the human motor cortex. Bursts of three pulses at 50 Hz repeated at 5 Hz produced lasting, reversible changes in corticospinal excitability measured by motor evoked potentials: the intermittent pattern potentiated responses and the continuous pattern depressed them, for up to an hour. This established that patterned TMS engages plasticity-like mechanisms, and it is the physiological basis for the theta-burst protocols now used in depression.
The study · 1
Huang et al., Theta burst stimulation of the human motor cortex · Neuron 2005;45(2):201-6
Mood & stress
Across 29 trials, high-frequency rTMS responded in 29% versus 10% on sham, remission 19% versus 5%
Pooling the trials, roughly three in ten people respond and about one in five get fully better with TMS, several times the sham rate, so around one extra person responds for every six treated.
Berlim and colleagues pooled 29 randomized, double-blind, sham-controlled trials of high-frequency rTMS for major depression. High-frequency rTMS was significantly superior to sham on both response (29.3% vs 10.4%) and remission (18.6% vs 5.0%), with pooled odds ratios of 3.3 and numbers needed to treat of 6 and 8. The effect held whether rTMS was used as monotherapy or as augmentation and in unipolar and mixed samples. Drop-out rates were low and similar between arms, indicating good tolerability.
The study · 1
Berlim et al., Response, remission and drop-out rates following high-frequency rTMS for major depression, systematic review and meta-analysis · Psychol Med 2014;44(2):225-39
A 3-minute theta-burst session matched standard 37-minute rTMS, 49% versus 47% response
A three-minute theta-burst session worked as well as the old thirty-seven-minute treatment, which lets a clinic treat far more people in a day.
The THREE-D trial (Blumberger et al.) was a large randomized non-inferiority study in treatment-resistant depression comparing iTBS with conventional 10 Hz left prefrontal rTMS, with a non-inferiority margin of 2.25 points on the 17-item Hamilton Rating Scale for Depression. Response (49% vs 47%) and remission (32% vs 27%) were comparable, and side effects, drop-out and tolerability were similar. Because iTBS delivers an equivalent result in a fraction of the time, it is the change that made high-throughput TMS clinics practical.
The study · 1
Blumberger et al., Effectiveness of theta burst versus high-frequency rTMS in patients with depression (THREE-D), a randomised non-inferiority trial · Lancet 2018;391(10131):1683-92
Drug-free rTMS remitted depression in 14% versus 5% on sham, about four times the odds
In a rigorous drug-free trial, about one in seven people with hard-to-treat depression got fully better with real TMS, against about one in twenty with a fake coil.
The Optimization of TMS (OPT-TMS) study was a multisite, double-blind, sham-controlled randomized trial funded by the US National Institute of Mental Health, testing daily left dorsolateral prefrontal rTMS as monotherapy in medication-resistant unipolar major depression. In the fixed three-week phase, remission on the primary outcome was reached by about 14% on active versus 5% on sham, with an odds ratio near 4.2. Because it used no concurrent antidepressant and a credible sham, it is one of the stronger single trials of rTMS efficacy, though the short course limits the remission numbers.
The study · 1
George et al., Daily left prefrontal rTMS for acute treatment of medication-resistant depression, a sham-controlled randomized trial (OPT-TMS) · Arch Gen Psychiatry 2010;67(5):507-16
Two-thirds of acute responders were still well at 12 months, under 30% relapsed
Of the people who got better from a course of TMS, most were still well a year later, though some needed a repeat course or maintenance sessions to stay there.
Dunner and colleagues followed 257 patients with pharmacoresistant major depression who had benefited from acute rTMS, over a naturalistic 12-month period. About two-thirds of acute responders maintained response, relapse was under 30%, and roughly a third received reintroduction of rTMS during the year. Patients also received treatment as usual, so this describes durability in real-world care, not the durability of a single course in isolation.
The study · 1
Dunner et al., A multisite naturalistic observational study of TMS for pharmacoresistant major depression, durability of benefit over a 1-year follow-up · J Clin Psychiatry 2014;75(12):1394-401
An intensive 5-day theta-burst protocol remitted 79% versus 13% on sham in a small trial
A compressed five-day version, ten short sessions a day, put most of a small group into remission, far more than the fake treatment and much faster than the usual six weeks.
Cole and colleagues tested SNT (previously SAINT), an accelerated intermittent theta-burst protocol delivering 10 sessions daily for 5 consecutive days, targeted using each participant's functional MRI connectivity. In this double-blind sham-controlled trial of 29 people with treatment-resistant depression, remission at some point in the 4-week follow-up was 79% with active and 13% with sham. The effect size is far larger than standard protocols, but the sample was small and single-site with brief follow-up, placing it at an emerging stage that needs larger, longer confirmation.
The study · 1
Cole et al., Stanford Neuromodulation Therapy (SNT), a double-blind randomized controlled trial · Am J Psychiatry 2022;179(2):132-41
Anxiety And Stress
Deep TMS responded in 38% versus 11% on sham for OCD at six weeks
For obsessive-compulsive disorder, about two in five people improved with deep TMS against about one in nine with a fake coil, and the improvement lasted at least a month after treatment.
Carmi and colleagues ran the pivotal prospective multicenter randomized double-blind sham-controlled trial of deep TMS for OCD using the H7 coil to reach the medial prefrontal and anterior cingulate cortex, with high-frequency stimulation delivered after individualized symptom provocation, five days a week for six weeks. Response (a 30% or greater reduction in Y-BOCS) was 38.1% for active and 11.1% for sham, sustained at the one-month follow-up. This trial supported the 2018 FDA clearance of deep TMS for OCD.
The study · 1
Carmi et al., Efficacy and safety of deep TMS for OCD, a prospective multicenter randomized double-blind placebo-controlled trial · Am J Psychiatry 2019;176(11):931-8
Addiction
Deep TMS raised the 4-week continuous quit rate to 19% versus 9% on sham
As an aid to quitting smoking, about one in five people stayed off cigarettes for a month with real TMS, against roughly one in eleven with a fake coil.
Zangen and colleagues reported the pivotal multicenter double-blind randomized controlled trial of repetitive (deep) TMS for smoking cessation in 262 chronic smokers who had failed prior quit attempts. Bilateral stimulation of the lateral prefrontal and insular cortices was delivered after a cue-induced craving procedure, daily for three weeks then weekly for three weeks. The four-week continuous quit rate through week 18, the primary endpoint, was 19.4% for active versus 8.7% for sham. This was the first large multicenter RCT of brain stimulation in addiction and supported the 2020 FDA clearance.
The study · 1
Zangen et al., Repetitive TMS for smoking cessation, a pivotal multicenter double-blind randomized controlled trial · World Psychiatry 2021;20(3):397-404
Go Deeper
- Depression: what actually helps: the full range of treatments, and where a later-line clinic option sits among the ones tried first.
- Ketamine and esketamine: another fast-acting clinic treatment for depression that has resisted medication.
- Vagus nerve stimulation: a related device treatment that stimulates the vagus nerve to reach the mood circuits.
- Quitting smoking: the behavioral and pharmacological work that deep TMS is meant to support.
Cautions For This Practice
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Seizures were rare, about 0.3 per 10,000 sessions across 587,000 sessions
Taylor and colleagues surveyed members of the Clinical TMS Society about seizures in their practices, capturing 586,656 sessions across 25,526 patients from all manufacturers, with 18 seizures reported, giving an overall rate of 0.31 per 10,000 sessions and 0.71 per 1,000 patients. Rates were higher for H-coil (deep) than figure-8 devices. The estimate is consistent with theta-burst safety data showing per-session seizure risk under about 0.02 to 0.03 percent, and it frames the seizure risk as low but not zero.Taylor et al., Seizure risk with repetitive TMS, survey results from over a half-million treatment sessions
Metal and electronic implants in or near the head
The strong magnetic field is the reason for the main hard limit. Ferromagnetic or electronic hardware in or near the head can heat, move, or malfunction in the field, so TMS is generally not done in that case. This includes aneurysm clips, cochlear implants, deep-brain or vagus-nerve stimulators, metal fragments in the eye or skull, and stents or coils near the treatment area. Dental fillings and braces are usually fine. The clinic asks this screening question before treatment, and it is the single most common reason someone cannot have TMS.
Seizure risk, rare but real
The one serious risk is a seizure: rare, about 0.3 per 10,000 sessions in a 586,656-session survey, and higher with the deeper-reaching coils. The risk rises with a personal history of seizures or epilepsy, with drugs or stimulants that lower the seizure threshold, and with sleep deprivation or heavy alcohol use. The clinic screens for all of these. A seizure during TMS is brief and self-limiting, and the setting is prepared for it.
Common, mild effects during and after a session
Most side effects are minor and settle over the first week or two. The most common are scalp discomfort or pain at the coil site during the pulses, and a headache afterward. Some people notice their face or jaw twitch while the pulses run. These tend to ease as tolerance builds, and the strength can be adjusted. The coil makes a loud click, so earplugs are worn, since the sound can affect hearing over a long course.
Bipolar disorder, pregnancy, and severe depression
In someone with bipolar disorder, stimulation aimed at lifting mood can occasionally tip toward a manic or agitated state, so it is used with a mood-stabilizing plan and specialist oversight. Data in pregnancy are limited. TMS avoids the systemic drug exposure that medication carries, which is part of why it is considered, but it is a decision to make with a clinician. For severe depression, TMS is one part of care under a clinician, not a reason to delay urgent help. If your low mood is severe, or you are having thoughts of harming yourself, reach a clinician or a crisis line now.
TMS is a real, regulated clinic treatment. It has consistent trial evidence for treatment-resistant depression and clearances for OCD and smoking cessation. Weigh the real size of the benefit, remember it can fade without maintenance, and keep the sham response in mind. Take the metal-implant and seizure cautions seriously, and work with a qualified clinic for anything touching your own care.
Common Questions
Does TMS actually work for depression?
Yes, for medication-resistant depression, at a real but moderate size. It is a later-line option: insurers usually cover it only after a few medications have been tried, and a full course typically costs several thousand dollars. It is reached for a serious, established case, after simpler steps have been tried.
What is a TMS session like, and is it the same as shock therapy?
No, it is a different treatment. During TMS the person sits awake in a chair, with no anesthesia and no sedation. Electroconvulsive therapy, or ECT, is the one people picture: it passes an electric current across the whole brain under general anesthesia to trigger a brief seizure on purpose. ECT is a stronger, more sedating treatment used for the most severe depression. TMS triggers no seizure, and the person drives home afterward.
Is TMS safe, and can it cause a seizure?
For most people TMS is well tolerated, with no drug left in the body and no recovery time. The one real risk is uncommon:
The one serious risk is a seizure: rare, about 0.3 per 10,000 sessions in a 586,656-session survey, and higher with the deeper-reaching coils.
Does the benefit last?
When a course works, the improvement often holds. Some need a repeat course or occasional maintenance sessions to sustain it. In follow-up studies most people who responded are still well a year later, and fewer than a third relapse within 12 months.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 9 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 15, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.